---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014005"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:19:51.212394+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IRADIMED Q3 revenue $18.3M (+11% YoY), raises FY EPS guidance, declares $0.15 dividend

## Summary
- Record Q3 revenue of $18.3M, up 11% YoY from $16.5M; GAAP diluted EPS $0.40, Non-GAAP $0.43.
- Raises FY 2024 GAAP EPS guidance to $1.49-$1.52 (from $1.37-$1.47) and Non-GAAP to $1.64-$1.67 (from $1.52-$1.62).
- Declares regular quarterly cash dividend of $0.15/share, payable Nov 25, 2024 to holders of record Nov 15, 2024.
- Q3 cash flow from operations was $9.1M, vs $1.4M in prior year; new Orlando facility capex ~$9M remaining.
- Q4 2024 guidance: revenue $18.8M-$19.2M, GAAP EPS $0.39-$0.42, Non-GAAP EPS $0.42-$0.45.

## SEC filing metadata
- accession: 0001558370-24-014005
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000155837024014005/0001558370-24-014005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000155837024014005/irmd-20241031x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014005
- JSON: https://secwatch.observer/filing/0001558370-24-014005.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.